Agree, but for the gap lovers - it is now closed. So, take from that what you will. Current market cap is circa $70M. We have, $23M-ish cash on hand, so circa $47M enterprise value.
In April 2024 - there was $5.2M cash on hand, shares issued were around 125M (I think) and shareprice was around 30c. Meaning, enterprise value was around $32M.
So, you can ask yourself, is the company worth just $15M more than it was before the distribution agreements, TGA access, commencing sales and completing the clinical trial? I am happy with my investment based on my answer to that question.
in the above i didnt factor in options and the shares on issue was ballpark. but its to illustrate, from a total value of company perspective, we are getting close to where we were pre-clinical trial and it doesn't pass the sniff test to go much lower IMO.
LTP Price at posting:
64.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)